TY - JOUR
T1 - Country-Specific Prevalence and Incidence of Youth-Onset Type 2 Diabetes
T2 - A Narrative Literature Review
AU - Lynch, Jane L.
AU - Barrientos-Pérez, Margarita
AU - Hafez, Mona
AU - Jalaludin, Muhammad Yazid
AU - Kovarenko, Margarita
AU - Rao, Paturi Vishnupriya
AU - Weghuber, Daniel
N1 - Funding Information:
Medical writing and editing support were provided by Ugo Battaglia, PhD, and Izabel James, MBBS, of Watermeadow Medical, an Ashfield Co., part of UDG Healthcare plc, funded by Novo Nordisk A/S. The manuscript was reviewed for medical accuracy by Divyalasya TVS, on behalf of Novo Nordisk. The authors are part of the Novo Nordisk Pediatric T2D Global Expert Panel. Other members of this group discussed initial ideas for this review with the authors, but did not contribute to its development. These other expert panel members are Timothy Bar-rett (University of Birmingham), Naim Shehadeh (Rambam Health Care Campus), and Serap Turan (Marmara University School of Medicine).
Funding Information:
All authors are members of the Novo Nordisk Pediatric Type 2 Diabetes Global Expert Panel and as such have received honoraria from Novo Nordisk. In addition, the authors declare the following: J.L. received fees from Novo Nordisk, NIH, and Daiichi Sankyo as a principal investigator and for consultancy work. M.B.-P. received fees from Novo Nordisk, Sanofi, Eli Lilly, and Opko as a principal investigator and from Pfizer, Abbott, Novo Nordisk, Sandoz, and Eli Lilly for consultancy work and lectures. M.H. received fees from Novo Nordisk for consultancy work. M.Y.J. received research grants from the Ministry of Health Malaysia, Newton-Ungku Omar Research Fund, and University Malaya. He also received honoraria from Nestle Nutrition Institute and Abbott Nutrition for consultation and lectures and from Novo Nordisk and Merck Sharp & Dohme as an expert panel reviewer. M.K. received fees from Novo Nordisk for consultancy work. P.R. received clinical trial payments from Novo Nordisk, Sanofi, Eli Lilly, IPCA laboratories, Hetero Pharma, Allergan, Parexel, and IQVIA; honorarium from the Indian Council of Medical Research; and employment benefits from DiabetOmics. D.W. declares no other conflicts of interest.
Publisher Copyright:
© 2020 The Author(s) Published by S. Karger AG, Basel.
PY - 2021/1
Y1 - 2021/1
N2 - Background: With increased awareness of type 2 diabetes (T2D) in children and adolescents, an overview of country-specific differences in epidemiology data is needed to develop a global picture of the disease development. Summary: This study examined country-specific prevalence and incidence data of youth-onset T2D published between 2008 and 2019, and searched for national guidelines to expand the understanding of country-specific similarities and differences. Of the 1,190 articles and 17 congress abstracts identified, 58 were included in this review. Our search found the highest reported prevalence rates of youth-onset T2D in China (520 cases/100,000 people) and the USA (212 cases/100,000) and lowest in Denmark (0.6 cases/100,000) and Ireland (1.2 cases/100,000). However, the highest incidence rates were reported in Taiwan (63 cases/100,000) and the UK (33.2 cases/100,000), with the lowest in Fiji (0.43 cases/100,000) and Austria (0.6 cases/100,000). These differences in epidemiology data may be partly explained by variations in the diagnostic criteria used within studies, screening recommendations within national guidelines and race/ethnicity within countries. Key Messages: Our study suggests that published country-specific epidemiology data for youth-onset T2D are varied and scant, and often with reporting inconsistencies. Finding optimal diagnostic criteria and screening strategies for this disease should be of high interest to every country. Trial Registration: Not applicable.
AB - Background: With increased awareness of type 2 diabetes (T2D) in children and adolescents, an overview of country-specific differences in epidemiology data is needed to develop a global picture of the disease development. Summary: This study examined country-specific prevalence and incidence data of youth-onset T2D published between 2008 and 2019, and searched for national guidelines to expand the understanding of country-specific similarities and differences. Of the 1,190 articles and 17 congress abstracts identified, 58 were included in this review. Our search found the highest reported prevalence rates of youth-onset T2D in China (520 cases/100,000 people) and the USA (212 cases/100,000) and lowest in Denmark (0.6 cases/100,000) and Ireland (1.2 cases/100,000). However, the highest incidence rates were reported in Taiwan (63 cases/100,000) and the UK (33.2 cases/100,000), with the lowest in Fiji (0.43 cases/100,000) and Austria (0.6 cases/100,000). These differences in epidemiology data may be partly explained by variations in the diagnostic criteria used within studies, screening recommendations within national guidelines and race/ethnicity within countries. Key Messages: Our study suggests that published country-specific epidemiology data for youth-onset T2D are varied and scant, and often with reporting inconsistencies. Finding optimal diagnostic criteria and screening strategies for this disease should be of high interest to every country. Trial Registration: Not applicable.
KW - Adolescent
KW - Child
KW - Diabetes mellitus type 2
KW - Incidence
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=85092660610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092660610&partnerID=8YFLogxK
U2 - 10.1159/000510499
DO - 10.1159/000510499
M3 - Review article
C2 - 32980841
AN - SCOPUS:85092660610
SN - 0250-6807
VL - 76
SP - 289
EP - 296
JO - Annals of Nutrition and Metabolism
JF - Annals of Nutrition and Metabolism
IS - 5
ER -